eicosapentaenoic acid
ApprovedSmall molecule
eicosapentaenoic acid is one of 136 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
5
Indications
6
Total Trials
0
Active Trials
135
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
223 competitors in Coronary Artery Disease
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsPhase 3
Leqvio
NovartisPhase 3
Vanrafia
NovartisPhase 3
eicosapentaenoic acid
SS.L.A. Pharma AG
Approved
Byetta
AstraZenecaPhase 3
Tekturna
Tibotec Pharmaceuticals, IrelandPhase 3
Kynamro
KKastle Therapeutics, LLC
Phase 3
Glutamine
SanofiPhase 3
Ridaforolimus
Merck & Co.Phase 3
Praluent
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cardiovascular1 trial
Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress
Completed·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 1·NCT00014027·97 enrolled
Myeloid Leukemia1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for eicosapentaenoic acid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SS.L.A. Pharma AG